Mocertatug rezetecan

DRUG5 trials

Sponsors

GlaxoSmithKline

Conditions

NeoplasmsNeoplasms, EndometrialOvarian NeoplasmsSolid Tumors

Phase 1

A Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Clinical Activity of Mocertatug Rezetecan for Injection in Participants With Advanced Solid Tumors (BEHOLD-1)

RecruitingNCT06431594

GlaxoSmithKlineNeoplasms, Solid Tumors

Start: 2024-07-02End: 2029-12-31Target: 675Updated: 2026-06-25

Phase 3

A Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy (BEHOLD-Endometrial01)

RecruitingNCT07286331

GlaxoSmithKlineNeoplasms, Endometrial

Start: 2026-06-04End: 2029-05-30Target: 600Updated: 2026-08-31

A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)

RecruitingNCT07286266

GlaxoSmithKlineOvarian Neoplasms

Start: 2026-06-18End: 2029-12-17Target: 450Updated: 2026-07-15

A Study to Investigate Mocertatug Rezetecan as Maintenance Treatment for Participants With MMRp Endometrial Cancer (BEHOLD-Endometrial02)

Not yet recruitingNCT07684599

GlaxoSmithKlineNeoplasms, Endometrial

Start: 2026-09-03End: 2031-09-18Target: 610Updated: 2026-09-01

Mo-Rez in First- Line (1L) Maintenance Treatment of Non-Homologous Recombination Deficient Ovarian Cancer (Non-HRd OC) [BEHOLD-Ovarian03]

Not yet recruitingNCT07694427

GlaxoSmithKlineOvarian Neoplasms

Start: 2026-10-09End: 2032-11-08Target: 720Updated: 2026-08-06

Related Papers

Abstract CT188: BEHOLD-1: A Phase 1 Dose Escalation Study of GSK5733584, a B7-H4-Targeted Antibody-Drug Conjugate, in Patients With Advanced Solid Tumors, Including Dose Expansion in Patients With Endometrial and Platinum-Resistant Ovarian Cancer

Cancer Research2025-04-25